Peripheral edema in an individual with treatment resistant major depressive disorder treated with olanzapine/fluoxetine combination

被引:0
|
作者
Srikanthan, Camellia [1 ]
Niciforos, Elaina [2 ]
McNeill, David [3 ]
机构
[1] Med Univ Amer, Dept Med, 27 Jackson Rd,Suite 302, Devens, MA 01434 USA
[2] Univ Toronto, 1265 Mil Trail, Scarborough, ON M1C 1A4, Canada
[3] Ontario Shores Ctr Mental Hlth Sci, Dept Integrated Hlth Serv, 700 Gordon St, Whitby, ON L1N 5S9, Canada
关键词
OLANZAPINE; FLUOXETINE; EFFICACY; SAFETY;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Olanzapine/fluoxetine combination therapy is a widely prescribed antipsychotic-antidepressant regimen for treatment resistant depression and is reported to have a side effect of peripheral edema. The theoretical underpinnings of peripheral edema in association with olanzapine/fluoxetine combination therapy are still unclear. Although peripheral edema associated with olanzapine/fluoxetine combination is rarely reported, the mechanism of drug interaction and effect on cytochrome P450 enzymes may induce it. We review the case of a middle-aged patient, who presented with peripheral edema after the administration of olanzapine/fluoxetine combination therapy.
引用
收藏
页码:100 / 102
页数:3
相关论文
共 50 条
  • [1] Olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder
    Thase, M. E.
    Corya, S. A.
    Osuntokun, O.
    Sanger, T. M.
    Case, M.
    Watson, S. B.
    Dube, S.
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2006, 9 : S235 - S236
  • [2] Olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder
    Thase, ME
    Corya, SA
    Osuntokun, O
    Sanger, TM
    Case, M
    Watson, SB
    Dubé, S
    [J]. BIOLOGICAL PSYCHIATRY, 2006, 59 (08) : 210S - 210S
  • [3] A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder
    Thase, Michael E.
    Corya, Sara A.
    Osuntokun, Olawale
    Case, Michael
    Henley, David B.
    Sanger, Todd M.
    Watson, Susan B.
    Dube, Sanjay
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2007, 68 (02) : 224 - 236
  • [4] Efficacy and Safety of Olanzapine/Fluoxetine Combination vs Fluoxetine Monotherapy Following Successful Combination Therapy of Treatment-Resistant Major Depressive Disorder
    Brunner, Elizabeth
    Tohen, Mauricio
    Osuntokun, Olawale
    Landry, John
    Thase, Michael E.
    [J]. NEUROPSYCHOPHARMACOLOGY, 2014, 39 (11) : 2549 - 2559
  • [5] Efficacy and Safety of Olanzapine/Fluoxetine Combination vs Fluoxetine Monotherapy Following Successful Combination Therapy of Treatment-Resistant Major Depressive Disorder
    Elizabeth Brunner
    Mauricio Tohen
    Olawale Osuntokun
    John Landry
    Michael E Thase
    [J]. Neuropsychopharmacology, 2014, 39 : 2549 - 2559
  • [6] Safety and efficacy of olanzapine plus fluoxetine in treatment-resistant major depressive disorder
    Shelton, R
    Tollefson, GD
    Tohen, M
    Jacobs, T
    Buras, W
    Spencer, K
    Gannon, KS
    Stahl, S
    [J]. SCHIZOPHRENIA RESEARCH, 1999, 36 (1-3) : 297 - 298
  • [7] COMBINATION OF FLUOXETINE WITH PEMOLINE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER
    METZ, A
    SHADER, RI
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1991, 6 (02) : 93 - 96
  • [8] The study of olanzapine plus fluoxetine in treatment-resistant major depressive disorder without psychotic features
    Shelton, RC
    Tohen, M
    Stahl, S
    Jacobs, T
    Gannon, K
    Tollefson, GD
    [J]. SCHIZOPHRENIA RESEARCH, 2000, 41 (01) : 193 - 193
  • [9] Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder
    Andersen, SW
    Clemow, DB
    Corya, SA
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2005, 66 (11) : 1468 - 1476
  • [10] Long-term use of olanzapine/fluoxetine combination for major depressive disorder: A 76-week study
    Corya, S
    Andersen, S
    Detke, H
    Van Campen, L
    Sanger, T
    Williamson, D
    Dube, S
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2003, 13 : S207 - S207